PI3K Inhibition for Squamous Cell Head and Neck Carcinoma

被引：5
|
作者：
Desilets, Antoine [1 ,2 ]
Soulieres, Denis [1 ]
机构：
[1] Ctr Hosp Univ Montreal CHUM, Pavillon C,1000 Rue St Denis, Montreal, PQ H2X 0C1, Canada
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
CANCER JOURNAL | 2022年 / 28卷 / 05期
关键词：
Head and neck squamous cell carcinoma; PI3K inhibitors; targeted therapy; PHOSPHOINOSITIDE 3-KINASE INHIBITOR; I DOSE-ESCALATION; BUPARLISIB BKM120; PACLITAXEL; RECURRENT; CHEMOTHERAPY; COMBINATION; EXPRESSION; RECEPTOR; NIVOLUMAB;
D O I：
10.1097/PPO.0000000000000618
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The phosphoinositide 3-kinase (PI3K) pathway is aberrantly activated in most head and neck squamous cell carcinomas, making it a prized target for targeted therapy development. Multiple PI3K inhibitors have been studied in early phase trials, with unfavorable risk-benefit ratios in molecularly unselected patient populations. Buparlisib, a potent pan-class I PI3K inhibitor, shows promising efficacy in combination with paclitaxel for advanced head and neck squamous cell carcinoma. Results of the phase III BURAN trial are awaited.
引用
收藏
页码：369 / 376
页数：8
相关论文
共 50 条
  • [1] Pharmacological PI3K inhibition in head and neck squamous cell carcinoma: A systematic review
    Alves, L. B.
    Moura, A. C.
    dos Santos, J. Amorim
    Borges, G. A.
    Guerra, E. N. S.
    TOXICOLOGY IN VITRO, 2023, 88
  • [2] Aurora kinases mediate resistance to PI3K inhibition in head and neck squamous cell carcinoma
    Sambandam, V.
    Mazumdar, T.
    Shen, L.
    Zhao, H.
    Peng, S.
    Wang, J.
    Johnson, F. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 106 (05): : 1184 - 1184
  • [3] Tumor-specific PI3K inhibition by targeted delivery in head and neck squamous cell carcinoma
    Mizrachi, A.
    Shamay, Y.
    Shah, J. K.
    Brook, S.
    Rajasekhar, V. K.
    Humm, J. L.
    Baselga, J.
    Heller, D. A.
    Haimovitz-Friedman, A.
    Scaltriti, M.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S66 - S66
  • [4] Evaluation of predictive biomarkers and resistance mechanisms of PI3K pathway inhibition in head and neck squamous cell carcinoma
    Mazumdar, Tuhina
    Byers, Lauren A.
    Ng, Patrick
    Mills, Gordon B.
    Peng, Shaohua
    Diao, Lixia
    Fan, Youhong
    Stemke-Hale, Katherine
    Heymach, John V.
    Myers, Jeffrey N.
    Glisson, Bonnie S.
    Johnson, Faye M.
    CANCER RESEARCH, 2014, 74 (19)
  • [5] The Role of the PI3K/Akt/mTOR Axis in Head and Neck Squamous Cell Carcinoma
    Jiang, Qian
    Xiao, Jingyi
    Hsieh, Yao-Ching
    Kumar, Neha Love
    Han, Lei
    Zou, Yuntao
    Li, Huang
    BIOMEDICINES, 2024, 12 (07)
  • [6] RAS/PI3K Crosstalk and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma
    Rampias, T.
    Giagini, A.
    Siolos, S.
    Matsuzaki, H.
    Sasaki, C.
    Scorilas, A.
    Psyrri, A.
    CLINICAL CANCER RESEARCH, 2014, 20 (11) : 2933 - 2946
  • [7] INVESTIGATING MECHANISMS OF PI3K INHIBITOR RESISTANCE IN HEAD AND NECK SQUAMOUS CELL CARCINOMA
    Vien, M.
    Young, C. D.
    Wang, X.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2018, 66 (01) : 110 - 110
  • [8] Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck
    Simpson, Daniel R.
    Mell, Loren K.
    Cohen, Ezra E. W.
    ORAL ONCOLOGY, 2015, 51 (04) : 291 - 298
  • [9] Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma
    Cai, Yi
    Dodhia, Sonam
    Su, Gloria H.
    ONCOTARGET, 2017, 8 (13) : 22203 - 22217
  • [10] Inhibition of PI3K and MEK in Combination With Radiation Therapy in Murine Model of Head and Neck Squamous Cell Carcinoma (HNSCC)
    Blas, K. G.
    Galoforo, S.
    Krueger, S. A.
    Wilson, T. G.
    Grills, I. S.
    Marples, B.
    Wilson, G. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E586 - E587
12345